Trump says U.S. is postponing some strikes as it negotiates end to war with Iran
The president’s announcement sent markets soaring and energy prices diving, as investors bet Iran’s blockade of a key shipping chokepoint could soon end. Source link
The president’s announcement sent markets soaring and energy prices diving, as investors bet Iran’s blockade of a key shipping chokepoint could soon end. Source link
Just over six months after it was announced, the Louvre has indefinitely postponed the competition launched in June 2025 to design an expansion of France’s most well-known art museum. The news was reported in Le Figaro Friday. The project, called Louvre—Nouvelle Renaissance, was announced by French President Emmanuel Macron in January of last year and aims to ease overcrowding at the museum, which welcomes some 9 million visitors a year. It was expected to be completed by 2031. The initial plan was to create a new entrance, update aging infrastructure, and—perhaps most controversially—build a new 33,000-square-foot exhibition space for the Mona Lisa. The plan was estimated to cost $778 million. Related Articles The Art Newspaper reported in January that the museum’s 2026 budget set aside $116 million for preliminary studies tied to the overhaul and $17.5 million for technical maintenance, including only $2.1 million for safety of the museum’s work. Last month, 350 Louvre staff members from three different unions staged a walkout in opposition to the redevelopment plan, stating that the museum should prioritize long-delayed technical upgrades and building …
In the field of infectious disease epidemiology, the most dangerous pathogens are not always those that dominate newspaper headlines. Often, they are those that remain on the margins of attention, reappearing periodically without ever attracting sustained political or scientific investment. The Nipah virus is a prime example of this overlooked threat. The recent cases reported in India should not be interpreted as an isolated episode, nor as an unexpected development. Nipah has been causing recurrent epidemics for over twenty years, with a well-documented capacity for zoonotic spillover and human-to-human transmission. Its epidemiological profile is already deeply concerning: high mortality rates, frequent involvement of healthcare workers, and a lack of approved vaccines or targeted antiviral therapies. From a scientific point of view, Nipah is not an unknown enemy. Its reservoirs are identified, its transmission routes widely understood, and its clinical progression well described. What remains insufficient is the translation of this knowledge into lasting preparedness. Surveillance systems continue to be activated only once cases are detected. Research funding remains sporadic. The development of countermeasures proceeds slowly, …